ARBs at recommended blood pressure-lowering doses ameliorate kidney injury, glomerulosclerosis, kidney hypertrophy and prevent interstitial fibrosis, most likely by inhibiting Ang II signalling through the AT1R and by improving Ang II hemodynamic actions [6,8]. The gene discussed is AGT; the disease is glomerulosclerosis.